This study, called the Kesimpta Pregnancy Registry, is looking at the effects of Kesimpta (ofatumumab) when taken by pregnant women with Multiple Sclerosis (MS). It's an observational study, meaning researchers will collect information from women who are already taking Kesimpta during pregnancy, rather than assigning them to a treatment. The main goal is to see how many babies born to these mothers have major birth defects. You can join if you are a pregnant woman, aged 18 to 100, diagnosed with MS, and are taking Kesimpta. This study aims to enroll 725 participants.

Study design

This is an observational study, not assigning any treatment. It will involve 725 participants and is conducted through two existing pregnancy registries.

What's involved

Pregnant women and their infants will be followed for a maximum of 21 months. The study will collect and assess data related to pregnancy and infant outcomes.

Compensation

Not stated in the trial record.

Follow-up

Participants will be followed for up to 21 months after pregnancy.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.